Aurobindo Pharma informs about disclosure

16 Aug 2024 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: further to its communication dated May 25, 2024, about Unit-III, a Formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, receiving Official Action Indicated (OAI) status by the US FDA. Subsequent to OAI, the unit has received a Warning Letter. There is no impact on the existing supplies to the US markets, the Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis. The company will keep the stock exchanges informed about further developments.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1240.70 -14.70 (-1.17%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.